Recent studies highlight the functional and clinically relevant impact of these multigene prognostic assays upon the adjuvant chemotherapy in ER+ early-stage breast carcinoma, indicating chemotherapy changes in approximately 25–30% of patients, with more changes against than for adjuvant chemotherapy [5]. The gene discussed is ESR1; the disease is breast carcinoma.